Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
FDA approves asthma indication for Dupixent® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent asthma, regardless of phenotype Only asthma …